Market Place
Sourcing Support
ChromaDex`s Niagen® IV Now Available in 200+ Restore Hyper Clinics
07 Nov 2024 //
BUSINESSWIRE
ChromaDex Corporation Reports Q3 2024 Financial Results
31 Oct 2024 //
BUSINESSWIRE
ChromaDex to Report Q3 2024 Financial Results October 31, 2024
28 Oct 2024 //
BUSINESSWIRE
ChromaDex To Report Q3 2024 Financial Results On Oct 31
24 Oct 2024 //
BUSINESSWIRE
ChromaDex to Participate in the 17th Annual LD Micro Main Event
23 Oct 2024 //
BUSINESSWIRE
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
20 Sep 2024 //
BUSINESSWIRE
ChromaDex Expands Niagen® IV And Injection Offerings
10 Sep 2024 //
BUSINESSWIRE
ChromaDex Marks 25 Years Of NAD+ Research For Healthy Aging
09 Sep 2024 //
BUSINESSWIRE
ChromaDex Patents Salt Forms Of NMNH, A Precursor To NAD+
19 Aug 2024 //
BUSINESSWIRE
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
07 Aug 2024 //
BUSINESSWIRE
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
05 Aug 2024 //
BUSINESSWIRE
ChromaDex Launches Niagen+ NAD+ Test Kit For Healthcare Practitioners
23 Jul 2024 //
BUSINESSWIRE
ChromaDex To Launch IV And Injectable Niagen At Wellness Clinics
16 Jul 2024 //
BUSINESSWIRE
ChromaDex to Join Russell 2000® Index
01 Jul 2024 //
BUSINESSWIRE
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharma-Grade IV & Inj Niagen
13 Jun 2024 //
BUSINESSWIRE
ChromaDex Gets US Orphan, Rare Pediatric Status For NRC In AT
07 Jun 2024 //
BUSINESSWIRE
ChromaDex wins orphan designation for rare ataxia drug
07 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Chromadex Lytham May 30 Event: Spring 2024 Investor Conference
23 May 2024 //
BUSINESSWIRE
ChromaDex Reports Q1 2024 Results on May 8
24 Apr 2024 //
BUSINESSWIRE
ChromaDex Launches Tru Niagen® at Sprouts
23 Apr 2024 //
BUSINESSWIRE
ChromaDex Announces Tru Niagen® is Now Third-Party Verified
26 Mar 2024 //
BUSINESSWIRE
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
06 Mar 2024 //
BUSINESSWIRE
ChromaDex Supports the US Military with Tru Niagen®
20 Dec 2023 //
BUSINESSWIRE
ChromaDex to Report Third Quarter 2023 Financial Results
31 Oct 2023 //
BUSINESSWIRE
ChromaDex and Zesty Paws® Crack the Code on Cellular Health
26 Oct 2023 //
BUSINESSWIRE
Study Builds on Growing Body of Evidence Showcasing Exogenous NMN Must be Converted to NR
24 Aug 2023 //
BUSINESSWIRE
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
ChromaDex to Report Second Quarter 2023 Financial Results
02 Aug 2023 //
BUSINESSWIRE
Findings from Published Abstracts Showcase the Importance of NAD+ in Glaucoma
18 Jul 2023 //
BUSINESSWIRE
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+)
16 Jun 2023 //
BUSINESSWIRE
ChromaDex to Participate in the LD Micro Invitational XIII
30 May 2023 //
BUSINESSWIRE
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
11 May 2023 //
BUSINESSWIRE
ChromaDex Corporation Reports First Quarter 2023 Financial Results
10 May 2023 //
BUSINESSWIRE
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
08 Mar 2023 //
BUSINESSWIRE
ChromaDex to Participate at Annual ROTH Capital Partners Conference
06 Mar 2023 //
BUSINESSWIRE
ChromaDex Announces Issuance of New U.S. Patent on NRH and NARH
22 Feb 2023 //
BUSINESSWIRE
A Letter from the ChromaDex Chief Executive Officer
21 Feb 2023 //
BUSINESSWIRE
ChromaDex Shares Promising Findings from a Study Showcasing CMAs, Featuring NR
31 Jan 2023 //
BUSINESSWIRE
ChromaDex Shares Findings from Clinical Study Demonstrating Oral NR (NAD+)
27 Dec 2022 //
BUSINESSWIRE
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN)
11 Nov 2022 //
BUSINESSWIRE
ChromaDex Announces Partnership with MyPharma2Go for Sales of Tru Niagen
01 Sep 2022 //
BUSINESSWIRE
Thorne Research, Inc. Loses Patent Challenge Decision
15 Aug 2022 //
BUSINESSWIRE
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
BUSINESS WIRE
ChromaDex to Report Second Quarter 2022 Financial Results
02 Aug 2022 //
BUSINESSWIRE
ChromaDex to Present at ASN, ISSN, and FASEB
15 Jun 2022 //
BUSINESSWIRE
ChromaDex Signs Sinopharm Xingsha Agreement for Tru Niagen into Mainland China
10 Jun 2022 //
BUSINESSWIRE
ChromaDex Corporation Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
22 Apr 2022 //
BUSINESSWIRE
ChromaDex Launches Tru Niagen Immune; Expands Innovative Product Portfolio
06 Apr 2022 //
BUSINESSWIRE
ChromaDex says Issuance of Additional New U.S. Continuation Patent
16 Mar 2022 //
BUSINESSWIRE
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results
09 Mar 2022 //
BUSINESSWIRE
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study
02 Mar 2022 //
BUSINESSWIRE
ChromaDex Bags New U.S. Continuation Patent for Nicotinamide Riboside
09 Feb 2022 //
BUSINESSWIRE
CERP Celebrates 100 Peer-Reviewed Published Studies on Niagen
31 Jan 2022 //
BUSINESSWIRE
ChromaDex Announces Results of New Pilot Clinical Trial of NR Supplementation
25 Jan 2022 //
BUSINESSWIRE
ChromaDex and Designs for Health Partner for New Product Development on Niagen
20 Jan 2022 //
BUSINESSWIRE
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside
18 Oct 2021 //
BUSINESSWIRE
